Layout Table~~~~1441~1441~~

Peripheral Neuropathy and Neuropathic Pain, 2008~
Published by BioPharm Reports, January 2008

This report estimates that Peripheral Neuropathy (PN) and Neuropathic Pain (NP) affect 170 to 270 million individuals globally. PN and NP are causally linked to a number of diseases, however diabetes, cancer and HIV alone are expected to increase the prevalence of PN and NP by more than 10% by 2012. PN and NP are areas of significant and critical unmet need. There are no cures for PN and NP is difficult to treat and often unresponsive to all available therapies. Today's armoury of drugs for the treatment of NP shows significant reliance on "second-indication" drugs, which were initially developed to treat other primary indications (e.g. anticonvulsants, antidepressants).~Published by BioPharm Reports, January 2008

This report estimates that Peripheral Neuropathy (PN) and Neuropathic Pain (NP) affect 170 to 270 million individuals globally. PN and NP are causally linked to a number of diseases, however diabetes, cancer and HIV alone are expected to increase the prevalence of PN and NP by more than 10% by 2012. PN and NP are areas of significant and critical unmet need. There are no cures for PN and NP is difficult to treat and often unresponsive to all available therapies. Today's armoury of drugs for the treatment of NP shows significant reliance on "second-indication" drugs, which were initially developed to treat other primary indications (e.g. anticonvulsants, antidepressants). This report gives a comprehensive update on all current drugs, together with the entire drug development pipeline, from pre-clinical through to Phase III, Registration and initial Launch. The pipeline includes 80 candidates being developed to treat PN and NP as a primary indication and 60 "second-indication" drugs. More than 300 patents published in the PN and NP field between 2002 and 2007 have also been assessed and presented, together with the identification of potential candidate molecules and drug targets which have not entered the development pipeline, but which may do so in the future. This report was written to provide a comprehensive update on therapeutic developments relating to PN and NP, both in tackling its most serious and debilitating symptoms, but also in targeting and potentially correcting the underlying disease mechanisms. Commercial evaluation and assessments including markets, market size, market sectors, sales and trends relating to PN and NP are also included in this report.

Drug Targets

Most current and developmental therapies for neuropathic conditions are directed at NP. Moreover, many of today's commonly used drugs in this area were developed for other indications, but subsequently were found to offer useful application in the treatment of NP. These include anticonvulsants, antidepressants and others. These "second indication" drugs represent around 10 pharmacological mechanisms including 5 hydroxytryptamine uptake inhibitors, cannabinoid CB1 agonists, carnitine acetyltransferase stimulants, GABA receptor agonists, NMDA antagonist, opioid mu receptor agonists, sodium channel antagonists, tumour necrosis factor alpha antagonists and others of unidentified pharmacological activity. In contrast, only a few molecules have been developed specifically for NP as a primary indication and these include an aldose reductase inhibitor, a membrane integrity agonist and an opioid kappa receptor agonist. However, the last ten years have seen important advances in the understanding of peripheral neuropathy and neuropathic pain at the biological and pathophysiological level and this is reflected in the numbers of new candidates in the drug development pipeline. Today, there are more than 40 drug types in development for the treatment of PN or NP as primary indications, more than 30 of which are directed at new drug targets. Whilst most of these are directed at NP, a number are targeting the underlying disease mechanisms, offering the hope that NP disease progression may be blocked or even reversed. The development and extension of new and existing molecules for the treatment of NP and PN as second indication drugs continues, and collectively these two groups (i.e. primary + secondary indication drugs) represent over 60 different drug types. Recent patent filings, 2002-2007, show a significant number of other therapeutic opportunities which have not entered the drug development pipeline, but which may do so in the future. This report identifies these candidates on the basis of their mechanism of action, drug target, developmental stage, by company and other relevant areas.

Background and Questions

PN and NP are causally linked to a number of conditions including diabetes, auto immunity, infection, cancer, drugs or toxins, the autonomic nervous system and hereditary diseases. It is estimated in this report that PN and NP currently affect 170 to 270 million individuals globally, figures that are set to increase by more than 10% by 2012. This report discusses the major peripheral neuropathies as well as neuropathic pain, together with prevalence, trends and treatments. Some of the questions considered in this report include:

1. which therapies are available for the treatment of PN and NP, their capabilities and failings, unmet need
2. What is happening in the developments pipeline, which candidates are nearest to market
3. what are the prevalences of the major neuropathies and what are the future anticipated trends
4. what strategies are being developed in the treatment of PN and NP, prospects of success and failure
5. which companies are developing new therapies for PN and NP
6. what are the current market sizes relating to PN and NP, including market sectors, sales and anticipated growth over the next 5 years

Report Contents~Peripheral Neuropathy and Neuropathic Pain, 2008 (PDF)|1111|~1441~3311~~

Neurodegenerative Disease Drug Market Analysis and Forecasts 2007~
Published by Visiongain, June 2007

With the recent Alzheimer's Association International Conference suggesting a new era of hope for sufferers of the illness, drug trials have shown some enlightening discoveries.~Published by Visiongain, June 2007

With the recent Alzheimer's Association International Conference suggesting a new era of hope for sufferers of the illness, drug trials have shown some enlightening discoveries.

But Alzheimer's isn't the only neurodegenerative disease and drug possibilities in this market continue to expand. Visiongain reveal that the market value for the Neurodegenerative market was worth over $16 billion in 2006, with revenues growth anticipated to exceed $18 billion in 2007. But what will it be in 2012? This report will tell you.

This report provides comprehensive information on the neurodegenerative diseases; Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Neuropathic pain. The report also covers rare genetic disorders-Huntington disease, Amyotrophic Lateral Sclerosis a niche market disease classification and also Prion diseases.

The report tackles how the significant rise in the growing population age "Baby Boom" generation, paralleled with longevity across the globe will be a major catalyst for the pharmaceutical/health care sector revenue growth in the long-term. It also analyses periods of sustained revenue growth, during 2007-2012, and how expectant patent expirations on some major blockbuster drugs with strong market shares will boost revenues in the generics market. The neurodegenerative report also sheds significant emphasis on the financial burden of the neurodegenerative diseases on national healthcares services.

Advancement in innovation in the global pharmaceutical and healthcare sector are expected to spiral global annual earnings for the major market leaders including Biogen Idec, Elan, Eli Lilly, Novartis and Pfizer.

The Visiongain Neurodegenerative Market report looks at a broad spectrum of therapies during disease treatment, including;

Biogen Idec and Elan's Tysabri for remitting relapsing Multiple Sclerosis GW's Cannabinoid product Sativex for Multiple Sclerosis Eli Lilly's Cymbalta and Pfizer's Lyrica indication for Neuropathic pain relief.

The report answers questions such as:

• n the next 5 years what will be the successful drugs
• Is stem cell research the answer for these diseases?
• Which of the current therapies show the greatest revenue generation potential?
• How will new drug development technologies impact on neuro disorders?

Visiongain's, Global Neurodegenerative Market Reports provides a rich insight on current research underway globally by leading industries in pharmaceutical/ Biotech sector coupled with ,unbiased market forecast, affected by views of Healthcare regulatory authorities.

Visiongain's Global Neurodegenerative Markets provides solutions to questions search as;

Which regions have the highest prevalence of these diseases today and by 2020?
What market share is accounted for by individual diseases in the neurodegenerative market?
What is the global cost of neurodegenerative diseases and the significant market shares?
How much the 2007 neurodegenerative market is to be valued at and what it will be worth by 2012?
Which are the market leaders in this class of therapy?
What are the current approved therapies in the market and are they more effective than present treatments?
Which first line drugs will be coming off patent by 2012 and what are implications to the market?
Which drugs have been withdrawn from the neurodegenerative market?
Which molecules are currently in the pipelines that are deemed to answer unmet therapeutic needs in the future?

Why You Must Buy This Report:

Visiongain's, Global Neurodegenerative Market Report, provides up-to-date analysis of present and future market illustrated by substantial number of charts and figures. It also discusses strategies employed by key players in the industries. This is a must buy report, as it will provide you with useful information on business opportunities in the big and niche markets.

The revenue forecasts generated in this report are exclusive to this report and are determined by the market, its future prospects in terms of patent protection, generic competition, life-cycle management, licensing agreements and market activity. With in-depth primary and secondary research, the forecasts run up to 2012. It will provide you with information on the dynamics of the Neurodegenerative Disease Market, and its operation until that time.

More key questions that this report answers:

What is the potential population treatment in the major global markets up to 2012?
Which are the main therapeutic agents dictating the pace of the market?
What companies are the major drivers in the market?
What is the present market activity and are the therapies effective?
What is the envisaged Market activity in 2012?
How will the growing population size affect the market in 2012 (Is big pharma up to the challenge?) How condensed is the Neurodegenerative drug pipeline?
What is big pharma doing to narrow unmet therapeutic demands?

Unique benefits to you when you order this report:

• Immediate access through our exclusive Reading Room
• You can access your report whichever country you are in without using hard drive space
• Primary research throughout. You will not find this information anywhere else
• Report stored in your reading room for ever
• Full searchable report when you buy the company or corporate editions
• Copies can be printed off for offline reading
• Packed with charts, analysis, figures, graphs and tables

Sample Pages~Neurodegenerative Disease Drug Market Analysis and Forecasts 2007 (Single User License)|1078|Neurodegenerative Disease Drug Market Analysis and Forecasts 2007 (Departmental License)|1079|Neurodegenerative Disease Drug Market Analysis and Forecasts 2007 (Company Wide License)|1080|~1441~3267~~

World Neurodegeneratives Disease Markets~
Published by Visiongain, February 2005

Is the neurodegeneratives disease market growing? Are current drug therapies valuable? What are the current unmet needs in this market? What is the future of this market? All the answers to these questions and other aspects of this $8bn market are to be found in visiongains World Neurodegeneratives Disease Markets, 2005-2009.~
Published by Visiongain, February 2005

Is the neurodegeneratives disease market growing? Are current drug therapies valuable? What are the current unmet needs in this market? What is the future of this market? All the answers to these questions and other aspects of this $8bn market are to be found in visiongains World Neurodegeneratives Disease Markets, 2005-2009.

The report examines the market for the following neurodegenerative diseases:

. Parkinson's Disease
. Alzheimer's Disease
. Multiple Sclerosis
. Huntington's Disease
. Amyotrophic Lateral Sclerosis (ALS)
. Neuropathies
. Prion diseases.

The report World Neurodegeneratives Disease Markets, 2005-2009 then goes on to examine in greater depth the financial detail, growth rates, new
developments, world-wide revenues and market share of the following:

. Parkinson's Disease
. Alzheimer's Disease
. Multiple Sclerosis

Of the three diseases drug treatments for Multiple Sclerosis dominates the
market and this market has the highest growth rate with a CAGR for the
period 2002-2009 of 19.8%

This report will show:

Key new treatments in the main three disease markets
Accurate revenues for individual drugs
Forecasts of drug revenues using visiongain's own forecast model
Significant future changes in the market
New developments and prominent pipeline drugs
The future potential of this market
What the rewards will be in investing in this market

Why You Must Buy this Report

With over 120 pages packed full of detail, tables, case studies, cutting -edge research studies, clinical trial information, key industry facts and figures. This report provides a concise guide to the neurodegeneratives disease markets. Visiongain's World Neurodegeneratives Disease Markets, 2005-2009 will become an essential tool into any company thinking of entering this market. You can not do without this report.

Sample Page 1

Sample Page 2~World Neurodegeneratives Disease Markets (Single user License PDF)|223|World Neurodegeneratives Disease Markets (Department License PDF)|593| World Neurodegeneratives Disease Markets (Company wide license PDF)|979|~1441~1803~~